Table 1.
Baseline demographics of patients who participated in the CRISS Cohort with baseline and 1 year data
| Baseline N | ||
|---|---|---|
|
| ||
| Age, mean (SD) | 150 | 50.4 (11.7) |
|
| ||
| Female, N (%) | 112 (75%) | |
|
| ||
| Race, N (%) | 150 | |
| Caucasian | 117 (78%) | |
| African American | 13 (9%) | |
| Asian | 11 (7%) | |
| Other or not provided | 9 (6%) | |
|
| ||
| Ethnicity, N (%) | 150 | |
| Hispanic | 16 (11%) | |
| Non-Hispanic | 134 (89%) | |
|
| ||
| Disease duration from first non-Raynaud symptom (yrs), mean (SD) | 144 | 1.59 (1.34) |
|
| ||
| Years since first Raynaud symptom, mean (SD) | 128 | 2.87 (2.49) |
|
| ||
| Years since first non-Raynaud symptom, mean (SD) | 129 | 2.32 (1.5) |
|
| ||
| Body mass index, mean (SD) | 96 | 26.02 (7.1) |
|
| ||
| Modified Rodnan skin score, mean (SD) | 150 | 21.4 (10.1) |
|
| ||
| Durometer, mean (SD) | 113 | 272.4 (64.5) |
|
| ||
| Forced vital capacity % predicted, mean (SD) | 140 | 82.32 (18.5) |
|
| ||
| Total lung capacity % predicted, mean (SD) | 109 | 87.83 (20.4) |
|
| ||
| Diffusion capacity of carbon monoxide % predicted, mean (SD) | 140 | 65.05 (20.9) |
|
| ||
| High-resolution computer tomography consistent with interstitial lung disease, N (%) | 99 | 79 (80) |
|
| ||
| 6-minute walking distance, mean (SD) | 50 | 421.6 (139.2) |
|
| ||
| Borg dyspnea (0–10 scale), mean (SD) | 46 | 1.92 (1.51) |
|
| ||
| Tendon friction rubs, N (%) | 140 | 40 (29) |
|
| ||
| Small joint contractures, N (%) | 133 | 78 (59) |
|
| ||
| Large joint contractures, N (%) | 133 | 39 (29) |
|
| ||
| Digital ulcers, N (%) | 150 | 15 (10) |
|
| ||
| Health assessment questionnaire-disability index, mean (SD) | 150 | 1.0 (0.8) |
|
| ||
| Digital ulcers VAS (0–150), mean (SD) | 134 | 20.9 (40.9) |
|
| ||
| Raynaud’s VAS (0–150), mean (SD) | 135 | 32.7 (40.8) |
|
| ||
| Breathing VAS (0–150), mean (SD) | 138 | 23.1 (36.7) |
|
| ||
| GI VAS (0–150), mean (SD) | 136 | 22.6 (34.4) |
|
| ||
| Disease severity VAS (0–150), mean (SD) | 138 | 56.4 (42.9) |
|
| ||
| Pain VAS (0–10), mean (SD) | 140 | 4.0 (2.8) |
|
| ||
| SF-36 PCS, mean (SD) | 138 | 37.6 (12.9) |
|
| ||
| SF-36 MCS, mean (SD) | 138 | 44.2 (6.0) |
|
| ||
| Physician global assessment VAS (0–10 cm), mean (SD) | 143 | 4.4 (2.2) |
|
| ||
| Patient global assessment VAS (0–10 cm), mean (SD) | 140 | 4.1 (4.0) |
|
| ||
| Antinuclear antibody, N (%) | 116 | 94 (81) |
|
| ||
| Anti-SCL-70 antibody, N (%) | 115 | 34 (30) |
|
| ||
| Serum creatine phosphokinase (IU/L), mean (SD) | 127 | 143.9 (184.5) |
|
| ||
| Serum platelets (k/uL), mean (SD) | 143 | 315.2 (102.5) |
|
| ||
| Serum brain natriuretic peptide (pg/ml), mean (SD) | 105 | 161.3 (824.0) |
|
| ||
| Serum erythrocyte sedimentation rate (mm/hr), mean (SD) | 121 | 23.4 (22.6) |
|
| ||
| Serum C-reactive protein (mg/dL), mean (SD) | 116 | 2.1 (4.9) |
VAS=visual analog scale; PCS=Physical component scale; MCS=Mental component scale